The estimated Net Worth of William Enright is at least $2.62 Million dollars as of 25 May 2018. William Enright owns over 1,300 units of Altimmune Inc stock worth over $2,623,066 and over the last 7 years William sold ALT stock worth over $0.
William has made over 3 trades of the Altimmune Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently William bought 1,300 units of ALT stock worth $663 on 25 May 2018.
The largest trade William's ever made was exercising 183,347 units of Altimmune Inc stock on 2 January 2018 worth over $14,668. On average, William trades about 69,605 units every 56 days since 2017. As of 25 May 2018 William still owns at least 365,839 units of Altimmune Inc stock.
You can see the complete history of William Enright stock trades at the bottom of the page.
William's mailing address filed with the SEC is C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners..., and Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: